Clinical trials: Viral Pneumonia
COVID-19
Understanding the Determinants of Mucosal Immunity and Optimizing the Diagnosis of Infection With SARS-CoV-2 Variants
One of the current health challenges in the face of the COVID-19 pandemic that started in Wuhan in 2019, and still responsible for successive waves, is to better understand and diagnose the infection.
- Trial name
- COVARIANT (NCT05858502)
- Testing
- Blood sample collection, Saliva sample collection, Nasopharyngeal and nasal sample collection
- Where
- France
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
COVID-19
A Phase 2 Study of APX-115 in Hospitalized Patients With Confirmed Mild to Moderate COVID-19.
This phase 2 study is to assess the safety and tolerability of APX-115 active doses compared to placebo following multiple oral dosing in hospitalized patients with confirmed, mild to moderate, symptomatic COVID-19.
- Trial name
- NCT04880109
- Testing
- APX-115
- Where
- 6 sites in United States
- Volunteers
- 16 people
- Sponsor
- Aptabio Therapeutics, Inc.
COVID-19, SARS-CoV-2 Infection
Whole-Virion Inactivated SARS-CoV-2 Vaccine (BBV152) for COVID-19 in Healthy Volunteers
Double blind, Multi-Centre study to evaluate the safety, reactogenicity, tolerability, and immunogenicity of three investigational vaccine groups and one placebo group in healthy volunteers who receive two intramuscular doses of…
- Trial name
- BBV152 (NCT04471519)
- Testing
- BBV152A - Phase I, BBV152B - Phase I, BBV152C - Phase I
- Where
- 12 sites in India
- Volunteers
- 755 people, healthy volunteers welcome
- Sponsor
- Bharat Biotech International Limited
COVID-19
Compassionate Use of REGN-COV2 for the Treatment of COVID-19
Compassionate Use requests will be considered for individuals who test positive for SARS-CoV-2 and where there is reasonable basis to believe that the patient is infected with a susceptible variant.
- Trial name
- NCT04617535
- Testing
- REGN10933+REGN10987 combination therapy
- Sponsor
- Regeneron Pharmaceuticals
COVID-19, COVID-19 Pandemic
PROlectin M, a Nucleocapsid TErminal GaleCTin Antagonist for COVID-19
A galectin antagonist prevents viral entry of Sars-CoV-2 virus by blocking the specific terminal on the surface receptors that enables the virus to enter human cells.
- Conditions
- COVID-19, COVID-19 Pandemic, COVID-19 Respiratory Infection, SARS-CoV2 Infection
- Trial name
- PROTECT (NCT05096052)
- Testing
- Galactomannan
- Volunteers
- 408 people
- Sponsor
- Bioxytran Inc.
Papillomavirus Infections, Coronavirus Disease (COVID-19)
Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)
The purpose of this study to evaluate the safety and immunogenicity of a 2-dose regimen of 9vHPV vaccine, where the first dose is administered concomitantly with a first dose of a 2-dose regimen of mRNA-1273 vaccine versus…
- Trial name
- NCT05119855
- Testing
- 9vHPV Vaccine, mRNA-1273 Vaccine
- Where
- 38 sites in United States
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
COVID-19
A Phase 2 Trial of the Immunogenicity and Safety of CVXGA Intranasal COVID Vaccine in Healthy Adults
The purpose of this trial is to evaluate immunogenicity and safety of CVXGA administered as a single intranasal dose against SARS-CoV-2 S-protein in participants.
- Trial name
- NCT05736835
- Testing
- CVXGA
- Where
- 10 sites in United States
- Volunteers
- 227 people, healthy volunteers welcome
- Sponsor
- CyanVac LLC
COVID-19 Infection
CRISIS2: A Phase 2 Study of the Safety and Antiviral Activity of Brequinar in Non-hospitalized Pts With COVID-19
This study will assess the efficacy and safety of DHODHi (brequinar) as an antiviral via 5 days of treatment of participants with positive COVID-19 and at least one symptom of COVI019 in an out-patient setting.
- Trial name
- CRISIS2 (NCT04575038)
- Testing
- Brequinar
- Where
- 14 sites in United States
- Volunteers
- 115 people
- Sponsor
- Clear Creek Bio, Inc.
COVID-19
A Randomized, Double-Blind, Single Center, Efficacy and Safety Study of Allogeneic HB-adMSCs Against COVID-19.
Hope Biosciences is conducting a research study of an investigational product called allogeneic adipose-derived mesenchymal stem cells (abbreviated as HB-adMSCs) to provide immune support against COVID-19.
- Trial name
- NCT04348435
- Testing
- HB-adMSCs
- Where
- United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Hope Biosciences Research Foundation
COVID-19
Dendritic Cell Vaccine, AV-COVID-19, to Prevent COVID-19 Infection
This is an adaptive Phase I trial of a vaccine consisting of autologous dendritic cells previously loaded ex vivo with SARS-CoV-2 spike protein, with or without GM-CSF, to prevent COVID-19 in adults.
- Trial name
- NCT04690387
- Testing
- AV-COVID-19, GM-CSF
- Where
- Indonesia
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Aivita Biomedical, Inc.
Influenza, Human+COVID-19
A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults
This early-stage study will look at a new mRNA vaccine that combines defenses against both seasonal flu and COVID-19 in terms of its safety and how it builds protection.
- Trial name
- NCT07464314
- Testing
- Investigational mRNA Seasonal Flu/COVID-19 Combination (Flu/COVm) Vaccine, Licensed Seasonal Influenza Vaccine, Licensed COVID-19 Vaccine
- Where
- 12 sites in United States
- Volunteers
- 225 people
- Sponsor
- GlaxoSmithKline
SARS-CoV-2
A Study of an Investigational mRNA-1273.815 COVID-19 Vaccine in Previously Vaccinated Adults
To evaluate immune responses of an Investigational mRNA-1273.815 vaccine against the Omicron subvariant strain (XBB.1.5) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
- Trial name
- NCT06354998
- Testing
- Investigational mRNA-1273.815, Licensed Spikevax Vaccine
- Where
- 7 sites in Australia
- Volunteers
- 217 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
SARS CoV-2
A Clinical Evaluation of COVID-19 Rapid Point of Care Antigen Tests
The current standard of care for diagnosis of Severe Acute Respiratory Syndrome associated Coronavirus -2 (SARS-CoV-2 ) infection involves sample collection to be prepared and measured via real time-polymerase chain reaction…
- Trial name
- NCT04568356
- Testing
- Direct Antigen Tests for COVID-19
- Where
- 3 sites in United States
- Volunteers
- 200 people
- Sponsor
- E25Bio, Inc.
Covid 19
GlowTest COVID-19 Antigen Home Test Kit QRI Use Study
The objective of the study is to determine the usability of the GlowTest COVID-19 Antigen Home Test in a simulated home use environment.
- Trial name
- NCT05140005
- Testing
- GlowTest COVID-19 Antigen Home Test
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Arion Bio
COVID-19 Pneumonia, Coronavirus Infections
Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells,NVSI-06-08) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above
This is randomized, blinded and controlled design. Among the randomly selected subjects who have been vaccinated with two doses of Inactivated COVID-19 vaccine (Vero cell), based on a step-wise approach, the subjects will receive…
- Trial name
- NCT05069129
- Testing
- Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-08), Inactivated COVID-19 vaccine (Vero cells), 3 doses Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-08)
- Where
- United Arab Emirates
- Volunteers
- 1,848 people, healthy volunteers welcome
- Sponsor
- National Vaccine and Serum Institute, China
COVID-19
Study of CPI-006 as Immunotherapy for Hospitalized COVID-19 Patients
This Phase 1 single-dose, dose-escalation study is an open label trial evaluating the safety of CPI-006, a humanized monoclonal antibody targeting the CD73 cell-surface ectonucleotidase, as immunotherapy for stable hospitalized…
- Trial name
- NCT04464395
- Testing
- CPI-006, Standard of Care
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Corvus Pharmaceuticals, Inc.
COVID-19
Home Usability Study of the SARS-CoV-2 (COVID-19) Test
The primary objective is to determine the usability of the SARS-CoV-2 Specimen Collection Materials for at-home collection and mailing of sample to the testing laboratory.
- Trial name
- NCT04395391
- Testing
- SARS-CoV-2
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Exact Sciences Corporation
Covid19, Corona Virus Infection
Study Designed to Evaluate the Effect of CimetrA in Patients Diagnosed With COVID-19
Multi-center multinational-controlled study in Israel, Brazil, Spain, and South-Africa. 240 adult patients who suffer from moderate COVID-19 infection.
- Trial name
- CimetrA (NCT05037162)
- Testing
- Biochemistry blood test, Hematology blood test, D-Dimer test (coagulation)
- Where
- Israel
- Volunteers
- 240 people
- Sponsor
- MGC Pharmaceuticals d.o.o
COVID-19 Pneumonia
The Development of a COVID19 Oral Vaccine Consisting of Bacillus Subtilis Spores
This is a study trial to assess the effectiveness of the immune response stimulated by the genetically engineered Bacillus subtilis which express and display Spike protein of the SARS-COV2 on the spore coat.
- Trial name
- NCT05057923
- Testing
- Bacillus subtilis
- Where
- Hong Kong
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- DreamTec Research Limited
Healthy, COVID-19
Study to Evaluate Safety, Tolerability, PK and the Food Effect on PK of ASC11/RTV Tablets in Healthy Subjects
This is a randomized, double-blind, placebo-controlled phase I clinical study evaluating the safety, tolerability, and pharmacokinetics of ASC11 plus ritonavir tablets in healthy subjects and an open-label, cross-over study…
- Trial name
- NCT05718518
- Testing
- ASC11 tablets, RTV tablets
- Where
- China
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.